# Risk of Urinary Retention With Retigabine

> **NCT01462656** · — · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 1 (estimated)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Non-EZG containing AED polytherapy
- **DRUG:** EZG containing AED polytherapy
- **DRUG:** Non-EZG AED monotherapy
- **DRUG:** EZG AED monotherapy

## Key facts

- **NCT ID:** NCT01462656
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 1 (ESTIMATED)
- **Why stopped:** This study was halted as the preliminary analysis revealed that the numbers were too low to warrant continuing the project
- **Last updated:** 2016-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01462656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01462656, "Risk of Urinary Retention With Retigabine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01462656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*